GOVX GeoVax Labs, Inc.

BEARISH Impact: 7/10 8-K
Horizon immediate Filed May 14, 2026 Processed 26d 6h ago SEC 0001437749-26-017070
8-K Item 2.02: Earnings release
Latest settled — T+5d
GOVX ▲ +195.94% at T+5d
SHORT call ✗ call lost -195.94% · α vs SPY -194.97% · entry $1.23 → $3.64
Next anchor: T+20d in 2d
Currently $1.28 · -4.07% from $1.23 entry (call sign-flipped)
Entry anchored
May 14, 2026
via day open
T+1d
+79.67%
call -79.67% · α -79.74%
$2.21
settled 26d ago
T+5d
+195.94%
call -195.94% · α -194.97%
$3.64
settled 20d ago
T+20d
call — · α —
in 2d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

GeoVax reported Q1 2026 net loss of $5.3M ($2.62/share) vs $5.4M ($11.20/share) in Q1 2025, with zero revenue after BARDA contract termination. Cash burn reduced cash to $1.3M from $3.1M at year-end 2025, providing less than one quarter of runway. The company continues to advance GEO-MVA toward a Phase 3 trial in H2 2026, but the cash position is critically low without a financing plan disclosed.

Actionable Insight

GeoVax has less than one quarter of cash runway with no revenue and no disclosed financing plan. The company will need to raise capital imminently to fund operations through the planned H2 2026 Phase 3 trial. Expect a dilutive offering or reverse split announcement. The stock is a high-risk binary event play on GEO-MVA trial initiation and financing execution.

Key Facts

  • Net loss of $5.3M for Q1 2026, essentially flat vs $5.4M in Q1 2025
  • Zero revenue in Q1 2026 vs $1.6M in Q1 2025 after BARDA contract termination
  • Cash balance fell to $1.3M at March 31, 2026 from $3.1M at December 31, 2025
  • Stockholders' equity collapsed to $494K from $3.8M at year-end 2025
  • Phase 3 GEO-MVA trial planned for H2 2026, but no financing to support it disclosed
  • Weighted average shares outstanding surged to 2,008,134 from 478,192 YoY (320% dilution)

Financial Impact

Cash burn of ~$1.8M/month with only $1.3M remaining — less than one quarter of runway. Zero revenue stream. Dilution of 320% YoY in weighted average shares.

revenuecashdilutionstockholders equity

Risk Factors

  • Cash runway of <1 quarter — imminent need for dilutive financing or bankruptcy risk
  • Zero revenue stream after BARDA contract termination
  • Stockholders' equity nearly wiped out at $494K vs $3.8M
  • Phase 3 trial initiation in H2 2026 contingent on raising capital
  • 320% YoY dilution in share count signals aggressive equity issuance

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (10 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-017070
Document: govx20260513_8k.htm0001437749-26-017070
Document: 0001437749-26-017070-index-headers.html0001437749-26-017070
Document: 0001437749-26-017070-index.html0001437749-26-017070
Document: 0001437749-26-017070.txt0001437749-26-017070
8-K Data (Synthetic)0001437749-26-017070
8 reports for GOVX
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+5▲ +24.55%May 7, 2026
Filters
Rows
Reports for GOVX — sortable, filterable
Type Now
Jun 4, 2026
5d ago
EFFECT
BEARISH ★ 5/10
$1.79 $1.65▲ +7.82%▲ +5.22%$1.28 (+28.49%)
May 26, 2026
14d ago
S-1
NEUTRAL ★ 3/10
$3.49 $2.67▼ −23.50%▼ −23.51%$1.28 (−63.32%)
May 19, 2026
21d ago
8-K
BEARISH ★ 7/10
$2.23 $2.75▼ −23.32%▼ −23.12%$1.28 (+42.60%)
May 14, 2026
26d ago
8-K
BEARISH ★ 7/10
$1.23 $2.21▼ −79.67%▼ −79.74%$1.28 (−4.07%)
May 7, 2026
4w ago
8-K
BEARISH ★ 7/10
$1.67 $1.48▲ +11.38%▲ +11.61%$1.28 (+23.35%)
Apr 22, 2026
6w ago
EFFECT
NEUTRAL ★ 5/10
$1.17 $1.15▼ −1.71%▼ −1.32%$1.28 (+9.40%)
Apr 20, 2026
7w ago
EFFECT
BEARISH ★ 6/10
$1.17 $1.14▲ +2.56%▲ +1.91%$1.28 (−9.40%)
Apr 15, 2026
7w ago
8-K
BEARISH ★ 7/10
$1.23 $1.24▼ −0.81%▲ +0.40%$1.28 (−4.07%)
Showing 8 of 8

US Market Status

Market Closed — Opens Thu (10h 55m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access